GNI Group Past Earnings Performance
Past criteria checks 4/6
GNI Group has been growing earnings at an average annual rate of 59.3%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been growing at an average rate of 26.9% per year. GNI Group's return on equity is 14.8%, and it has net margins of 31.7%.
Key information
59.3%
Earnings growth rate
57.4%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | 26.9% |
| Return on equity | 14.8% |
| Net Margin | 31.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
After Leaping 48% GNI Group Ltd. (TSE:2160) Shares Are Not Flying Under The Radar
Sep 20
GNI Group's (TSE:2160) Shareholders Should Assess Earnings With Caution
Aug 27GNI Group Ltd. (TSE:2160) Stock's 37% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 06Investors Continue Waiting On Sidelines For GNI Group Ltd. (TSE:2160)
Jun 20Is GNI Group (TSE:2160) Using Too Much Debt?
Apr 12News Flash: Analysts Just Made An Incredible Upgrade To Their GNI Group Ltd. (TSE:2160) Forecasts
Mar 19Further Upside For GNI Group Ltd. (TSE:2160) Shares Could Introduce Price Risks After 40% Bounce
Feb 28Revenue & Expenses Breakdown
How GNI Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 22,655 | 7,186 | 16,609 | 2,709 |
| 30 Jun 24 | 23,647 | 6,766 | 16,231 | 2,723 |
| 31 Mar 24 | 27,752 | 9,550 | 15,935 | 2,610 |
| 31 Dec 23 | 26,010 | 8,094 | 15,293 | 2,557 |
| 30 Sep 23 | 25,204 | 1,525 | 13,024 | 2,502 |
| 30 Jun 23 | 23,360 | 1,370 | 12,379 | 2,709 |
| 31 Mar 23 | 17,691 | 35 | 11,154 | 2,712 |
| 31 Dec 22 | 17,418 | 388 | 10,966 | 2,545 |
| 30 Sep 22 | 15,915 | 848 | 9,953 | 2,417 |
| 30 Jun 22 | 14,379 | 801 | 9,047 | 2,240 |
| 31 Mar 22 | 12,751 | 985 | 8,223 | 2,080 |
| 31 Dec 21 | 12,690 | 1,066 | 7,959 | 2,015 |
| 30 Sep 21 | 12,356 | 2,086 | 7,188 | 1,805 |
| 30 Jun 21 | 11,858 | 1,955 | 6,645 | 1,525 |
| 31 Mar 21 | 11,520 | 1,558 | 6,252 | 1,438 |
| 31 Dec 20 | 9,773 | 1,258 | 5,180 | 1,243 |
| 30 Sep 20 | 9,066 | 367 | 4,806 | 1,056 |
| 30 Jun 20 | 8,407 | 247 | 4,502 | 1,036 |
| 31 Mar 20 | 7,996 | 194 | 4,498 | 839 |
| 31 Dec 19 | 7,446 | 181 | 4,334 | 758 |
| 30 Sep 19 | 6,734 | 147 | 3,853 | 658 |
| 30 Jun 19 | 6,279 | 154 | 3,706 | 585 |
| 31 Mar 19 | 5,581 | 258 | 3,290 | 567 |
| 31 Dec 18 | 5,018 | -200 | 2,998 | 530 |
| 30 Sep 18 | 4,802 | 47 | 2,730 | 527 |
| 30 Jun 18 | 4,095 | -130 | 2,401 | 413 |
| 31 Mar 18 | 3,310 | -337 | 2,103 | 302 |
| 31 Dec 17 | 2,648 | -175 | 1,740 | 268 |
| 30 Sep 17 | 1,939 | -97 | 1,521 | 243 |
| 30 Jun 17 | 1,473 | -111 | 1,261 | 238 |
| 31 Mar 17 | 1,347 | -406 | 1,139 | 257 |
| 31 Dec 16 | 1,306 | -513 | 1,118 | 274 |
| 30 Sep 16 | 1,117 | -858 | 878 | 580 |
| 30 Jun 16 | 1,073 | -956 | 979 | 519 |
| 31 Mar 16 | 1,093 | -752 | 1,048 | 452 |
| 31 Dec 15 | 1,016 | -623 | 1,049 | 379 |
| 30 Sep 15 | 928 | -440 | 1,071 | 139 |
| 30 Jun 15 | 814 | -360 | 963 | 139 |
| 31 Mar 15 | 651 | -345 | 823 | 139 |
| 31 Dec 14 | 474 | -327 | 715 | 139 |
| 30 Sep 14 | 334 | -527 | 364 | 427 |
| 30 Jun 14 | 254 | -787 | 511 | 427 |
| 31 Mar 14 | 202 | -769 | 438 | 427 |
| 31 Dec 13 | 183 | -730 | 367 | 427 |
Quality Earnings: 2160 has a high level of non-cash earnings.
Growing Profit Margin: 2160's current net profit margins (31.7%) are higher than last year (6.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2160's earnings have grown significantly by 59.3% per year over the past 5 years.
Accelerating Growth: 2160's earnings growth over the past year (371.2%) exceeds its 5-year average (59.3% per year).
Earnings vs Industry: 2160 earnings growth over the past year (371.2%) exceeded the Biotechs industry 4%.
Return on Equity
High ROE: 2160's Return on Equity (14.8%) is considered low.